FDA Looks Likely To Split Decision On Mepolizumab Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
An advisory committee was nearly unanimous that GSK’s clinical program demonstrated efficacy and safety for the IL-5 inhibitor in adult patients with severe asthma, but voted no on approval in patients ages 12-17.